AN ACT relating to prescription drugs.
HB 388 is a broad prescription-drug and controlled-substances bill that revises multiple Kentucky statutes governing Medicaid pharmacy benefits, controlled-substance prescribing, the prescription drug monitoring program, licensure discipline, interstate data sharing, and health insurance drug coverage. A central feature is the expansion and modernization of medication synchronization programs in Medicaid and private health plans, allowing patients with chronic conditions to align refill dates when clinically appropriate, with prorated daily cost-sharing but non-prorated dispensing fees.
The bill also updates Kentucky’s controlled-substance framework by revising definitions in KRS Chapter 218A, strengthening electronic prescribing requirements, and expanding the state’s monitoring system to include medicinal cannabis data alongside Schedule II-V controlled substances. It requires more detailed reporting, broader access for certain regulators and law-enforcement users, quarterly pattern reviews by the Office of Inspector General, and continuing education and training related to the monitoring system. It also adds or clarifies exemptions for certain settings such as hospice, nursing facilities, hospitals, research protocols, and charitable health care services.
HB 388 amends KRS 205.529, 218A.010, 218A.172, 218A.182, 218A.202, 218A.205, 218A.245, and 304.17A-165. In practical terms, it expands state oversight of prescription drugs and controlled substances while also creating new patient-access and pharmacy-administration rules, especially for medication synchronization and electronic prescribing. It broadens the prescription monitoring infrastructure to cover medicinal cannabis and requires additional reporting, data-sharing, training, and disciplinary coordination among the Cabinet for Health and Family Services, licensing boards, law enforcement, and Medicaid. It also affects insurers and pharmacy benefit managers by requiring synchronization coverage for chronic medications, while preserving an exclusion for controlled substances in the refill-override provision.
The recorded vote history indicates overwhelming support and little to no visible opposition: the House passed the veto override 92-0, and the Senate passed third reading 37-0. No committee transcript excerpts were provided, so the available record suggests the bill was broadly viewed as a technical and policy update to Kentucky’s drug-monitoring and prescription rules rather than a controversial measure. The unanimous votes also suggest consensus around both the public-health and regulatory goals of the bill.
The bill’s main points of potential contention are the expanded monitoring and disclosure framework and the stricter prescribing controls, especially the limits on Schedule II opioid prescribing, the reporting of overdose-related toxicology screens, and the inclusion of medicinal cannabis data in the monitoring system. Health-care practitioners, pharmacists, and cannabis businesses are directly affected by new registration, reporting, training, and compliance obligations, while privacy concerns may arise from the broader data access authorized for licensing boards, law enforcement, and certain state entities. At the same time, the bill includes multiple exemptions and safeguards, which appear designed to balance diversion control with clinical flexibility and patient access.